Search

Author/Creator Espié, Pascal

1. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. (March 2020)

Authors:
Fisher, Benjamin A; Szanto, Antonia; Ng, Wan-Fai; Bombardieri, Michele; Posch, Maximilian G; Papas, Athena S; Farag, Arwa M; Daikeler, Thomas; Bannert, Bettina; Kyburz, Diego; Kivitz, Alan J; Carsons, Steven E; Isenberg, David A; Barone, Francesca; Bowman, Simon J; Espié, Pascal; Floch, David; Du...
Journal:
Lancet
Issue:
Volume 2:Number 3(2020)
Page Start:
e142
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. First‐in‐human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti‐CD40 monoclonal antibody. Issue 2 (6th December 2019)

Authors:
Espié, Pascal; He, YanLing; Koo, Phillip; Sickert, Denise; Dupuy, Cyrielle; Chokoté, Edwige; Schuler, Roland; Mergentaler, Heidi; Ristov, Jacinda; Milojevic, Julie; Verles, Aurelie; Groenewegen, Andrea; Auger, Anita; Avrameas, Alexandre; Rotte, Michael; Colin, Laurence; Tomek, Charles S.; Hernand...
Journal:
American journal of transplantation
Issue:
Volume 20:Issue 2(2020)
Page Start:
463
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search